Vaxart, Inc. (VXRT) shareholders
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 243M shares
Institutional holders
4
1 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
5 buys · 0 sales
Net bought $30.64K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.10%), Rajeev Shah (9.10%) and 1 more | 15,384,615 | 9.10% | 13G (passive) | Jan 18, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VXRT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Heritage Wealth Advisors | 29,655 | 0.01% | $17.94K | – | 0.00% |
| Lvm Capital Management Ltd/Mi | 25,000 | 0.01% | $15.00K | – | 0.00% |
| Kingswood Wealth Advisors, LLC | 10,005 | 0.00% | $6.05K | New | 0.00% |
| Archer Investment Corp | 30 | 0.00% | $18 | +15 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0.0% | 1 / 1 | 0 / 2 | 0M | 0M |
| Q1 2026 | 5 | 0M | 0.0% | 2 / 1 | 0 / 1 | 0M | 0M |
| Q4 2025 | 5 | 0M | 0.0% | 1 / 1 | 0 / 13 | 0M | 2M |
| Q3 2025 | 17 | 2M | 1.0% | 3 / 5 | 1 / 84 | 0M | 21M |
| Q2 2025 | 98 | 23M | 9.5% | 17 / 20 | 18 / 10 | 4M | 8M |
| Q1 2025 | 92 | 27M | 11.2% | 12 / 15 | 24 / 12 | 1M | 10M |
| Q4 2024 | 93 | 36M | 14.7% | 13 / 23 | 24 / 18 | 2M | 4M |
| Q3 2024 | 100 | 38M | 15.5% | 18 / 15 | 26 / 17 | 4M | 5M |
| Q2 2024 | 100 | 41M | 16.7% | 22 / 21 | 22 / 24 | 22M | 22M |
| Q1 2024 | 104 | 41M | 16.9% | 29 / 27 | 19 / 11 | 26M | 1M |
| Q4 2023 | 87 | 17M | 6.9% | 7 / 24 | 20 / 16 | 2M | 4M |
| Q3 2023 | 96 | 18M | 7.6% | 8 / 19 | 30 / 23 | 1M | 11M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven Lo | President, Chief Exec Officer, Director | 2,585,606 | 1.06% | Mar 26, 2026 |
| Jeroen Nicolaas Grasman | Chief Financial Officer | 545,605 | 0.22% | May 21, 2026 |
| Sean Tucker | SVP, Chief Scientific Officer | 943,336 | 0.39% | Mar 31, 2026 |
| James F. Cummings | Chief Medical Officer | 924,177 | 0.38% | Mar 31, 2026 |
| Edward B. Berg | SVP, General Counsel | 755,368 | 0.31% | Mar 26, 2026 |
| Phillip E. Lee | Chief Financial Officer | 631,619 | 0.26% | Mar 26, 2025 |
| Raquel C. Bono | Director | 78,800 | 0.03% | Oct 20, 2026 |
| Kevin Finney | Director | 244,171 | 0.10% | Jul 20, 2026 |
| James B. Breitmeyer | Director | 87,115 | 0.04% | Jul 17, 2026 |
| David E. Wheadon | Director | 86,150 | 0.04% | Jul 17, 2026 |
| Elaine J. Heron | Director | 135,966 | 0.06% | Jul 17, 2026 |
| W. Mark Watson | Director | 173,525 | 0.07% | Jul 17, 2026 |
| Michael J. Finney | Director | 702,840 | 0.29% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Raquel C. Bono Director | Oct 16, 2026 | Award | +78,800 | – | – | 78,800 |
| Kevin Finney Director | Jul 16, 2026 | Award | +39,400 | – | – | 244,171 |
| W. Mark Watson Director | Jul 16, 2026 | Award | +39,400 | – | – | 173,525 |
| James B. Breitmeyer Director | Jul 16, 2026 | Award | +8,315 | – | – | 87,115 |
| David E. Wheadon Director | Jul 16, 2026 | Award | +39,400 | – | – | 86,150 |
| Elaine J. Heron Director | Jul 16, 2026 | Award | +39,400 | – | – | 135,966 |
| W. Mark Watson Director | May 22, 2026 | Buy | +10,000 | $0.65 | $6.50K | 134,125 |
| Jeroen Nicolaas Grasman Chief Financial Officer | May 19, 2026 | Tax withholding | −31,395 | $0.61 | $19.15K | 545,605 |
| James B. Breitmeyer Director | Apr 23, 2026 | Award | +78,800 | – | – | 78,800 |
| James F. Cummings Chief Medical Officer | Mar 28, 2026 | Tax withholding | −3,292 | $0.65 | $2.14K | 924,177 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 28, 2026 | Tax withholding | −3,924 | $0.65 | $2.55K | 882,811 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 24, 2026 | Tax withholding | −36,418 | $0.69 | $25.13K | 886,735 |
| Steven Lo President, Chief Exec Officer, Director | Mar 24, 2026 | Tax withholding | −126,028 | $0.69 | $86.96K | 2,485,606 |
| James F. Cummings Chief Medical Officer | Mar 24, 2026 | Tax withholding | −30,551 | $0.69 | $21.08K | 927,469 |
| Edward B. Berg SVP, General Counsel | Mar 24, 2026 | Tax withholding | −36,418 | $0.69 | $25.13K | 755,368 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 18, 2026 | Tax withholding | −8,072 | $0.63 | $5.09K | 923,153 |
| James F. Cummings Chief Medical Officer | Mar 18, 2026 | Tax withholding | −6,772 | $0.63 | $4.27K | 958,020 |
| Edward B. Berg SVP, General Counsel | Mar 18, 2026 | Tax withholding | −8,072 | $0.63 | $5.09K | 791,786 |
| Steven Lo President, Chief Exec Officer, Director | Mar 18, 2026 | Tax withholding | −22,425 | $0.63 | $14.13K | 2,611,634 |
| James F. Cummings Chief Medical Officer | Mar 16, 2026 | Award | +227,000 | – | – | 964,792 |
| Jeroen Nicolaas Grasman Chief Financial Officer | Mar 16, 2026 | Award | +227,000 | – | – | 577,000 |
| Edward B. Berg SVP, General Counsel | Mar 16, 2026 | Award | +115,000 | – | – | 799,858 |
| Steven Lo President, Chief Exec Officer, Director | Mar 16, 2026 | Award | +846,500 | – | – | 2,634,059 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 16, 2026 | Award | +200,000 | – | – | 931,225 |
| Edward B. Berg SVP, General Counsel | Feb 2, 2026 | Tax withholding | −9,265 | $0.61 | $5.65K | 684,858 |
| James F. Cummings Chief Medical Officer | Feb 2, 2026 | Tax withholding | −7,965 | $0.61 | $4.86K | 737,792 |
| Sean Tucker SVP, Chief Scientific Officer | Feb 2, 2026 | Tax withholding | −9,265 | $0.61 | $5.65K | 731,225 |
| Steven Lo President, Chief Exec Officer, Director | Dec 4, 2025 | Award | +151,351 | – | – | 1,841,712 |
| Steven Lo President, Chief Exec Officer, Director | Dec 4, 2025 | Tax withholding | −54,153 | $0.37 | $20.04K | 1,787,559 |
| W. Mark Watson Director | Nov 17, 2025 | Buy | +5,000 | $0.41 | $2.05K | 124,125 |
| W. Mark Watson Director | Nov 17, 2025 | Buy | +15,000 | $0.41 | $6.15K | 119,125 |
| Elaine J. Heron Director | Nov 17, 2025 | Buy | +16,783 | $0.41 | $6.88K | 96,566 |
| Elaine J. Heron Director | Nov 17, 2025 | Buy | +23,217 | $0.39 | $9.05K | 79,783 |
| Kevin Finney Director | Aug 15, 2025 | Buy | +50,000 | $0.37 | $18.50K | 204,771 |
| Kevin Finney Director | Aug 15, 2025 | Buy | +50,000 | $0.35 | $17.50K | 154,771 |
| Kevin Finney Director | Jul 30, 2025 | Buy | +25,874 | $0.38 | $9.83K | 104,771 |
| W. Mark Watson Director | Jul 29, 2025 | Buy | +10,000 | $0.41 | $4.10K | 104,125 |
| Kevin Finney Director | Jul 28, 2025 | Buy | +20,000 | $0.40 | $8.00K | 78,897 |
| Kevin Finney Director | Jul 25, 2025 | Buy | +20,000 | $0.39 | $7.80K | 58,897 |
| Kevin Finney Director | Jul 17, 2025 | Buy | +794 | $0.38 | $302 | 38,897 |
| Kevin Finney Director | Jun 13, 2025 | Award | +6,103 | – | – | 38,103 |
| W. Mark Watson Director | Jun 13, 2025 | Award | +16,000 | – | – | 94,125 |
| Michael J. Finney Director | Jun 13, 2025 | Award | +16,000 | – | – | 702,840 |
| David E. Wheadon Director | Jun 13, 2025 | Award | +16,000 | – | – | 46,750 |
| Elaine J. Heron Director | Jun 13, 2025 | Award | +16,000 | – | – | 56,566 |
| Jeroen Nicolaas Grasman Chief Financial Officer | May 19, 2025 | Award | +350,000 | – | – | 350,000 |
| Steven Lo President, Chief Exec Officer, Director | May 19, 2025 | Buy | +100,000 | $0.49 | $49.00K | 100,000 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 28, 2025 | Tax withholding | −3,913 | $0.42 | $1.64K | 740,490 |
| James F. Cummings Chief Medical Officer | Mar 28, 2025 | Tax withholding | −3,292 | $0.42 | $1.38K | 745,757 |
| Phillip E. Lee Chief Financial Officer | Mar 24, 2025 | Award | +406,000 | – | – | 631,619 |
| Edward B. Berg SVP, General Counsel | Mar 24, 2025 | Award | +406,000 | – | – | 694,123 |
| Steven Lo President, Chief Exec Officer, Director | Mar 24, 2025 | Award | +1,405,000 | – | – | 1,632,638 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 24, 2025 | Award | +406,000 | – | – | 744,403 |
| James F. Cummings Chief Medical Officer | Mar 24, 2025 | Award | +406,000 | – | – | 749,049 |
| Phillip E. Lee Chief Financial Officer | Mar 18, 2025 | Tax withholding | −8,050 | $0.57 | $4.59K | 225,619 |
| Edward B. Berg SVP, General Counsel | Mar 18, 2025 | Tax withholding | −8,050 | $0.57 | $4.59K | 288,123 |
| James F. Cummings Chief Medical Officer | Mar 18, 2025 | Tax withholding | −6,772 | $0.57 | $3.86K | 343,049 |
| Sean Tucker SVP, Chief Scientific Officer | Mar 18, 2025 | Tax withholding | −8,050 | $0.57 | $4.59K | 338,403 |
| Steven Lo President, Chief Exec Officer, Director | Mar 18, 2025 | Tax withholding | −22,362 | $0.57 | $12.75K | 227,638 |
| James F. Cummings Chief Medical Officer | Feb 2, 2025 | Tax withholding | −7,964 | $0.68 | $5.42K | 318,837 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
2M shares short
Days to cover
4.0
At 1M shares a day
Change since last report
+0.5%
From 2M shares
Short volume, 20 days
53.7%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vaxart's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,850 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael J. Finney Former Director | Dec 8, 2025 | 40,000 | $14.40K | Dec 8, 2025 | Private Acquisition from Issuer/Affiliate |
| Phillip E. Lee Former Executive Officer | May 27, 2025 | 81,364 | $37.43K | May 27, 2025 | Deferred stock award |
See a number that looks wrong?